Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000034915 | SCV000623319 | pathogenic | Bloom syndrome | 2023-09-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln1283*) in the BLM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BLM are known to be pathogenic (PMID: 17407155). This variant is present in population databases (rs367543031, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with Bloom syndrome (PMID: 17407155). ClinVar contains an entry for this variant (Variation ID: 42089). For these reasons, this variant has been classified as Pathogenic. |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV000034915 | SCV002500247 | pathogenic | Bloom syndrome | 2022-03-09 | criteria provided, single submitter | clinical testing | Variant summary: BLM c.3847C>T (p.Gln1283X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 4e-06 in 251478 control chromosomes. c.3847C>T has been reported in the literature as a homozygous genotype in at-least one in individual affected with Bloom Syndrome (example, German_2007). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
| Ambry Genetics | RCV002354185 | SCV002621693 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-07-28 | criteria provided, single submitter | clinical testing | The p.Q1283* pathogenic mutation (also known as c.3847C>T), located in coding exon 19 of the BLM gene, results from a C to T substitution at nucleotide position 3847. This changes the amino acid from a glutamine to a stop codon within coding exon 19. This variant was reported in a homozygous state in 1/134 patients from a Bloom syndrome registry (German J et al. Hum. Mutat. 2007 Aug;28:743-53). In a pan-ethnic population screen for Bloom syndrome carrier status, this variant was reported in 3/22864 individuals (Perreault-Micale C et al. Mol Genet Genomic Med. 2015 Jul;3:363-73). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
| Baylor Genetics | RCV000034915 | SCV004210898 | pathogenic | Bloom syndrome | 2023-04-16 | criteria provided, single submitter | clinical testing | |
| Counsyl | RCV000034915 | SCV000793460 | likely pathogenic | Bloom syndrome | 2017-08-16 | no assertion criteria provided | clinical testing | |
| Natera, |
RCV000034915 | SCV002090616 | pathogenic | Bloom syndrome | 2017-03-16 | no assertion criteria provided | clinical testing |